Skip to main content
. 2020 Jul 7;11:1437. doi: 10.3389/fimmu.2020.01437

Figure 5.

Figure 5

rBmSP44 active immunization protects against B. microti infection in BALB/c mice. (A) The levels of anti-BmSP44 antibody in the sera of immunized mice or control (adjuvant) mice were measured by ELISA at different time points. (B) Active immunization with rBmSP44 or adjuvant control BALB/c mice were challenged with 1 × 107 erythrocytes with B. microti and blood samples were obtained on day 3, 6, and 9 p.i. Revervse transcription qPCR analysis of the expression of B.microti at different developmental stages. After reverse transcription, the cDNA was used as a template for qPCR using SYBR Green. Each reaction was performed in triplicate. All fold changes were relative to the different stage. Significant differences are as follows: ***P < 0.001. (C–I) Parasitaemia is quantified as the percentage of iRBCs by blood smears on day 3, 6, and 9 p.i. Giemsa staining of blood smears from control (C,E,G) and rBmSP44 immunized group (D,F,H). Sections obtained on day 3 (C,D), 6 (E,F), and 9 (G,H) p.i. (I) Parasitemia of the immunized group and that of the control group caculated by blood smears observed under microscope. The degree of infection were 20, 75, and 35% in control Adjuvant-vaccinated group (n = 5) and 12, 60, and 24% in rBmSP44 vaccinated group (n = 5), respectively. The values shown for each group are the mean + SEM of the parasitemia. Significant differences are as follows: **P < 0.01.